Aug 12, 2020
Emmes Announces its Role in Phase 1 COVID-19 Vaccine Trial
Aug 05, 2020
SRI International Awarded Contract Worth Up to $100M from National Institute of Allergy and Infectious Diseases for Radiation/Nuclear Medical Countermeasures
Jun 10, 2020
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
Jun 09, 2020
Soligenix to Present at the MedInvest Infectious Disease and Immunology Investor Conference
Jun 05, 2020
U.S. Support for Drugmakers Fuels Effort to Secure Shortest Timeline for COVID-19 Vaccine
May 26, 2020
Emmes Announces its Contribution to NIH ACTT Clinical Trial for Remdesivir
May 04, 2020
Emmes Announces Dr. Joe Sliman as New Chief Medical Officer
Apr 22, 2020
Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team
Apr 06, 2020
Three Long-Time Emmes Employees Are Named VPs
Feb 24, 2020
NIH Awards Booz Allen $147M IT Support Contract
Feb 05, 2020
Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials
Feb 04, 2020
Plex Pharmaceuticals Awarded $600,000 Phase I NIH SBIR Grant to Develop Broad-Spectrum Antivirals to Treat Flavivirus Infections
Nov 28, 2019
Ridgeback Biotherapeutics LP announces publication of mAb114 results in the New England Journal of Medicine
Nov 14, 2019
Integral Molecular to Advance Vaccine Discovery with NIH Contract for $5.5M
Oct 23, 2019
BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine
Oct 04, 2019
Joshua Milner, MD, to Lead Pediatric Allergy, Immunology, and Rheumatology at Columbia University Irving Medical Center and NewYork-Presbyterian Morgan Stanley Children's Hospital
Oct 01, 2019
BlueWillow Awarded NIH Contract to Advance Development of its Therapeutic Peanut Allergy Vaccine
Sep 25, 2019
Versatope Awarded up to $17.9M for a Universal Influenza Vaccine
Sep 23, 2019
UM School Of Medicine's Center For Vaccine Development And Global Health Receives NIH Contract Of Up To More Than $200 Million For Influenza Research
Sep 03, 2019
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Investigational Prophylactic Vaccine for the Prevention of Respiratory Syncytial Virus in Older Adults